ORELABRUTINIB, AN IRREVERSIBLE INHIBITOR OF BRUTON'S TYROSINE KINASE (BTK), FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IB/IIA DOSE-FINDING STUDY

被引：4
|
作者：
Li, R. [1 ]
Zhu, X. [2 ]
Liu, S. [3 ]
Zhang, X. [4 ]
Xie, C. [5 ]
Fu, Z. [6 ]
Huang, A. [7 ]
Sun, L. [8 ]
Liu, D. [9 ]
Zhao, J. [10 ]
Wu, L. [11 ]
Qin, Z. [12 ]
Li, S. [13 ]
Liu, Y. [14 ]
Li, Z. [1 ]
机构：
[1] Peking Univ, Peoples Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China
[2] Fudan Univ, Huashan Hosp, Dept Rheumatol & Immunol, Shanghai, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Rheumatol & Immunol, Zhengzhou, Peoples R China
[4] Guangdong Prov Peoples Hosp, Dept Rheumatol & Immunol, Guangzhou, Peoples R China
[5] Bengbu Med Coll, Affiliated Hosp 1, Dept Rheumatol & Immunol, Bengbu, Peoples R China
[6] Shanxi Med Univ, Hosp 1, Dept Rheumatol & Immunol, Taiyuan, Peoples R China
[7] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Rheumatol & Immunol, Wuhan, Peoples R China
[8] Nanjing Drum Tower Hosp, Dept Rheumatol & Immunol, Nanjing, Peoples R China
[9] Shenzhen Peoples Hosp, Dept Rheumatol & Immunol, Shenzhen, Peoples R China
[10] Peking Univ Third Hosp, Dept Rheumatol & Immunol, Beijing, Peoples R China
[11] Univ Hong Kong, Shenzhen Hosp, Dept Rheumatol & Immunol, Shenzhen, Peoples R China
[12] InnoCare Pharma Ltd, Dept Pharmacol, Beijing, Peoples R China
[13] InnoCare Pharma Ltd, Dept Biostat, Beijing, Peoples R China
[14] InnoCare Pharma Ltd, Dept Autoimmune Med Res, Beijing, Peoples R China
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.5086a
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LB0005
引用
收藏
页码：210 / 210
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial
    Wallace, Daniel J.
    Dorner, Thomas
    Pisetsky, David S.
    Sanchez-Guerrero, Jorge
    Patel, Anand C.
    Parsons-Rich, Dana
    Le Bolay, Claire
    Drouin, Elise E.
    Kao, Amy H.
    Guehring, Hans
    Dall'Era, Maria
    ACR OPEN RHEUMATOLOGY, 2023, 5 (01) : 38 - 48
  • [2] Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
    Morand, Eric
    Pike, Marilyn
    Merrill, Joan T.
    van Vollenhoven, Ronald
    Werth, Victoria P.
    Hobar, Coburn
    Delev, Nikolay
    Shah, Vaishali
    Sharkey, Brian
    Wegman, Thomas
    Catlett, Ian
    Banerjee, Subhashis
    Singhal, Shalabh
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 (02) : 242 - 252
  • [3] Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
    Isenberg, David
    Furie, Richard
    Jones, Nicholas S.
    Guibord, Pascal
    Galanter, Joshua
    Lee, Chin
    McGregor, Anna
    Toth, Balazs
    Rae, Julie
    Hwang, Olivia
    Desai, Rupal
    Lokku, Armend
    Ramamoorthi, Nandhini
    Hackney, Jason A.
    Miranda, Pedro
    de Souza, Viviane A.
    Jaller-Raad, Juan J.
    Fernandes, Anna Maura
    Salinas, Rodrigo Garcia
    Chinn, Leslie W.
    Townsend, Michael J.
    Morimoto, Alyssa M.
    Tuckwell, Katie
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 (10) : 1835 - 1846
  • [4] BARICITINIB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM A PHASE 2, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
    Wallace, D. J.
    Furie, R. A.
    Tanaka, Y.
    Kalunian, K. C.
    Mosca, M.
    Petri, M. A.
    Dorner, T.
    Cardiel, M. H.
    Bruce, I. N.
    Gomez, E.
    Carmack, T.
    Janes, J. M.
    Linnik, M. D.
    Silk, M.
    Hoffman, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 59 - 59
  • [5] Bromocriptine in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled study
    Alvarez-Nemegyei, J
    Cobarrubias-Cobos, A
    Escalante-Triay, F
    Sosa-Munoz, J
    Miranda, JM
    Jara, LJ
    LUPUS, 1998, 7 (06) : 414 - 419
  • [6] GANGLIOSIDES IN THE TREATMENT OF DIABETIC NEUROPATHY - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY
    LINGETTI, M
    COTO, V
    RENGO, F
    SGAMBATO, S
    INNOCENTI, A
    FIORI, MG
    DIABETES NUTRITION & METABOLISM, 1992, 5 (04) : 275 - 282
  • [7] PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF A REVERSIBLE B CELL INHIBITOR, XMAB®5871, IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    Merrill, Joan
    June, Joshua
    Koumpouras, Fotios
    Machua, Wambui
    Khan, Mohammad Faisal
    Askanase, Anca
    Khosroshahi, Arezou
    Sheikh, Saira
    James, Judith A.
    Guthridge, Joel
    Rathi, Gaurav
    Burington, Bart
    Foster, Paul
    Zack, Debra
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 761 - 762
  • [8] Baricitinib in Patients with Systemic Lupus Erythematosus: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Wallace, Daniel J.
    Furie, Richard
    Tanaka, Yoshiya
    Kalunian, Kenneth C.
    Mosca, Marta
    Petri, Michelle
    Dorner, Thomas
    Cardiel, Mario H.
    Bruce, Ian N.
    Gomez, Elisa
    DeLozier, Amy M.
    Janes, Jonathan
    Linnik, Matthew D.
    de Bono, Stephanie
    Silk, Maria E.
    Hoffman, Robert W.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [9] Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus
    Tam, LS
    Li, EK
    Wong, CK
    Lam, CWK
    Szeto, CC
    LUPUS, 2004, 13 (08) : 601 - 604
  • [10] Bromocriptine in systemic lupus erythematosus: A double-blind, randomized placebo-controlled study.
    AlvarezNemegyei, J
    CovarrubiasCobos, A
    EscalanteTriay, F
    SosaMunoz, G
    Jara, LJ
    ARTHRITIS AND RHEUMATISM, 1996, 39 (09): : 1351 - 1351
12345